BLTE - Belite Bio Inc. to present at the Deutsche Bank ADR Virtual Investor Conference on 8 November 2023 | Benzinga
SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ:BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Belite Bio's Chief Scientific Officer, Nathan Mata will present at the Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference (dbVIC) on November 8. This virtual investor conference is aimed exclusively at introducing global companies with ADR programs to investors.
| DATE: |
| November 8, 2023 |
| TIME: |
| 11:00 AM ET |
| LINK: |
| https://bit.ly/3rhvMzf |
This will be a live, interactive online event in which investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.
Participation is free of charge.
Recent Company Highlights
- Tinlarebant is Belite Bio's orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD).
- Currently, there are no FDA approved treatments ...